

## BDG SYNTHESIS

### Certificate of Analysis

BDG Synthesis certifies that this reference material meets or exceeds the specifications stated herein.


Barry Dent

Barry R. Dent, PhD, Director  
19 August 2014

**Name:** 6 $\alpha$ ,9 $\alpha$ -Difluoroprednisolone-17-butyrate-d<sub>6</sub>

**CAS Number:** 23640-96-2 (unlabelled)

**Structure:**



**Molecular Weight:** C<sub>25</sub>H<sub>26</sub>D<sub>6</sub>F<sub>2</sub>O<sub>6</sub> = 472.55

**Lot Number:** BDG 9235.1

**Appearance:** White, crystalline solid

**Corrected Purity:** 98.7 % (HPLC) - 0.2 % (acetone) - 3.0 % (water) = 95.5 %

**Isotopic Purity:** Under 0.5 % d<sub>0</sub>

**Re-test Date:** 19 August 2019

**Storage and Handling:** Temperature: refrigerate for prolonged storage; may be handled and shipped at ambient temperature.

Humidity: not believed to be hygroscopic; may be handled in normal laboratory atmosphere.

Light: protect from strong sunlight.

Caution: only experienced laboratory personnel should handle the material. Solutions of this compound undergo 17,21 transesterification when heated.

## Identity and Purity

### Proton NMR Spectrum

Identity: the signals are consistent with the proposed structure and in accord with literature where available.

Isotopic Labelling: signals at the sites of deuteration are greatly diminished, compared with the spectrum of unlabelled material, indicating clean deuteration, with the exception of the methylene signal adjacent to the ester group, where significant H/D exchange is observed.

Residual Solvents: a small amount of acetone (0.2 % w/w) is observed. .

Impurities: no significant impurities are evident in the spectrum.

### Carbon-13 NMR Spectrum

Identity: the signals are consistent with the proposed structure and in accord with literature where available.

Isotopic Labelling: signals at the sites of deuteration have collapsed to small multiplets compared with the spectrum of unlabelled material, indicating clean deuteration, with the exception of the methylene signal adjacent to the ester group, where significant H/D exchange is observed.

### High-resolution Mass Spectrum (ESI+)

Found  $m/z$  495.2401.  $C_{25}H_{26}D_6F_2NaO_6$   $[M+Na]^+$  requires  $m/z$  495.2435. The deviation of 6.8 ppm is somewhat outside normally accepted limits for the establishment of identity by HRMS, and the mass spectral data should be considered in conjunction with other identity criteria. No signal for  $d_0$  material was seen (detection limit about 0.5 %). Substantial signals are observed for  $d_5$  and  $d_7$  material.

### HPLC

A sharp, symmetrical peak is observed (98.7 %). Note: in the absence of reference materials for preparing calibration curves, it is assumed that all peaks have the same detector response. Where possible, the conditions of analysis follow a pharmacopeial or literature method, or have been adapted from same.

### Elemental Analysis

|                                       |           |  |
|---------------------------------------|-----------|--|
|                                       | Found:    | C 61.60, H 5.80, D 2.67 %                |
| $C_{25}H_{26}D_6F_2O_6 \cdot 0.8H_2O$ | Requires: | C 61.66, H 5.71, D 2.48 %, $H_2O$ 2.96 % |
| $C_{25}H_{26}D_6F_2O_6$               | Requires: | C 63.54, H 5.55, D 2.56 %                |

The elemental analyses fall somewhat outside those expected for anhydrous material; the presence of water is reasonably expected from the method of purification and/or the type of material, and the "best-fit" hydrated molecular formula is given. In the absence of a Karl-Fischer water analysis, we recommend that the "best-fit" water content be used when determining corrected purity.



The available quantity of custom-synthesised material is always small, and this limits the extent and type of analytical data which can be obtained. This Certificate is presented in descriptive format for use by analytical chemists who are trained in the use of custom-synthesised materials. Custom materials often contain higher levels of residual solvents and/or water, and we urge you to use the corrected purity where needed rather than the raw HPLC purity. This compound is intended for use as an analytical reference material and it is not for human administration. Structures are shown with relative stereochemistry unless otherwise specified.

The re-test date is assigned from experience gained with the material in the laboratory and/or on storage. It is not possible to perform formal storage studies because of the small amount of material available.




# BDG SYNTHESIS

Proton NMR Spectrum of 6 $\alpha$ ,9 $\alpha$ -Difluoroprednisolone-17-butyrate (top) and 6 $\alpha$ ,9 $\alpha$ -Difluoroprednisolone-17-butyrate-d<sub>6</sub> (bottom) in DMSO-d<sub>6</sub>






Lot Number: BDG 9235.1






**BDG SYNTHESIS**

Carbon-13 NMR Spectrum of 6 $\alpha$ ,9 $\alpha$ -Difluoroprednisolone-17-butyrate (top) and 6 $\alpha$ ,9 $\alpha$ -Difluoroprednisolone-17-butyrate-d<sub>6</sub> (bottom) in DMSO-d<sub>6</sub>




Lot Number: BDG 9235.1



BDG - Analysis of 6a,9a-Difluoroprednisolone-17-butyrate-d6

Column : Phenomenex Luna C18(2) 5um 250 x 4.6 mm  
 Guard : Phenomenex Security Guard C18 RP 4 x 3 mm  
 Mobile Phase A : 10 mM diPotassium Hydrogen Phosphate pH = 7.0  
 Mobile Phase B : Acetonitrile  
 Gradient ( A:B ) : T0=60:40, T20=25:75, T24=25:75, T27=25:75, T30=60:40  
 Flow Rate : 1.0 mL/min . . . . . Sample Solvent : 1:1 Water : Acetonitrile  
 Column Temperature : 20C . . . . . Injection Volume : 10 uL . . . . . Detection : UV at 240 nm

|                    |                          |                      |                |
|--------------------|--------------------------|----------------------|----------------|
| <b>Sample Name</b> | BDG 9235.1               | <b>Instrument</b>    | AnalyticalLC01 |
| <b>Acquisition</b> | 19/08/2014, 17:51:34     | <b>Method (rev.)</b> | LC10413b ( 6)  |
| <b>Sequence</b>    | BDG_19Aug2014c           | <b>Vial Position</b> | 2              |
| <b>Operator</b>    | solvation010\cerityadmin | <b>Injection</b>     | 2 of 2         |



Area Percent Report

| Peak# | RT        | Peak Height | Peak Area  | Width      | Area %   |
|-------|-----------|-------------|------------|------------|----------|
| 1     | 5.73 min  | 1.7974      | 20.6127    | 0.1778 min | 0.166 %  |
| 2     | 8.66 min  | 0.2677      | 3.0270     | 0.1599 min | 0.024 %  |
| 3     | 9.61 min  | 0.6020      | 5.3524     | 0.1337 min | 0.043 %  |
| 4     | 10.18 min | 0.7256      | 6.7302     | 0.1402 min | 0.054 %  |
| 5     | 10.99 min | 1262.2896   | 12252.7122 | 0.1492 min | 98.681 % |
| 6     | 12.23 min | 2.1203      | 21.7718    | 0.1578 min | 0.175 %  |
| 7     | 13.28 min | 4.8942      | 50.0104    | 0.1532 min | 0.403 %  |
| 8     | 13.83 min | 4.4941      | 41.8376    | 0.1426 min | 0.337 %  |
| 9     | 15.66 min | 0.3882      | 3.3283     | 0.1380 min | 0.027 %  |
| 10    | 20.60 min | 1.1171      | 11.1073    | 0.1520 min | 0.089 %  |